Abstract library

2151 results for "Neuroendocrine cancer".
#2958 The Blood-based Multigenomic NETest Accurately Identifies Neuroendocrine Transformed Prostate Cancer
Introduction: Neuroendocrine differentiation and an aggressive phenotype is an important feature of castration-resistant prostate cancer (CRPC). Current biomarkers are unable to detect these advanced, treatment refractory variants.
Conference: 17th Annual ENETS Conference (2020)
Category: Biomarkers
Presenting Author: Professor Mark Kidd
#2978 Policy Barriers to Increasing Access to Radioligand Therapy for Neuroendocrine Cancers
Introduction: Radioligand therapy is a relatively new treatment approach used in a small number of neuroendocrine cancers and has been shown to improve overall survival and quality of life. Yet because it uses radioactivity, there are particular barriers to its greater integration into cancer care. As neuroendocrine cancers are rare, it is all the more urgent that these barriers be understood and overcome so that this treatment modality can become available to all patients who may benefit.
Conference: 17th Annual ENETS Conference (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Christine Merkel
#2024 Metachronous Primary Cancers in Neuroendocrine Tumor Patients
Introduction: Historically there has been an association between neuroendocrine tumours (NETs) and second primary cancers (Stronge et al 2014). However, this has not been well characterised.
Conference: 15th Annual ENETS conference (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: Tracey Genus
#2724 Overall Survival and Progression Free Survival of Patients with Large Cell Neuroendocrine Lung Cancer and Combined Large Cell Neuroendocrine Lung Cancer Treated in Clinical Stage I-IV
Introduction: Large cell neuroendocrine cancer (LCNEC) is characterized rare incidence and poor prognosis.
Conference: 17th Annual ENETS Conference (2020)
Category: Trials in Progress/Trials in Concept
Presenting Author: Anna Łowczak
#2910 Virotherapy Shows Promising Efficacy in Neuroendocrine Cancers
Introduction: So far, there have been only two clinical studies using virotherapeutics to treat neuroendocrine cancers (NCT00314925 & NCT02749331). Notably, none of these approaches employed a clinically approved virotherapeutic compound.
Conference: 17th Annual ENETS Conference (2020)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Prof. Ulrich M. Lauer
#2251 Neuroendocrine Testicular Tumour. An Unusual Issue.
Introduction: Neuroendocrine tumours can arise from neuroendocrine cells throughout the body. Location on testis is rare, accounting less than 1% of all testicular malignancies.
Conference: 15th Annual ENETS conference (2018)
Category: Case reports
Presenting Author: Ana Landa
#622 Evaluation of Mucin and Neuroendocrine Expression in Diffuse Gastric Cancer with Signet Ring Cell Morphology
Introduction: A proportion of diffuse gastric carcinoma, according to the Lauren classification system, has signet ring cell morphology. Signet ring cells are characterized by a peripherally placed nucleus and a central amorphous substance, which is reported to be mucin based on Periodic Acid Schiff positivity (PAS). PAS is not a specific staining method for mucin. Neuroendocrine expression has previously been reported in tumor cells in diffuse type gastric cancer.
Conference: 10th Annual ENETS Conference (2013)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: MD, PhD Øystein Sørdal
#1443 Second Primary Malignancies Incidence in Patients with Neuroendocrine Tumours – Retrospective Review of 454 Neuroendocrine Tumour Cases
Introduction: Increased incidence of second primary malignancies (SPM) in patients (pts) with neuroendocrine tumors (NET) has been reported.
Conference: 13th Annual ENETS conference (2016)
Category: Clinical cases/reports
Presenting Author: MD Karolina Poczkaj
#2021 1-Year Survival Rates for Neuroendocrine Tumor Patients in England
Introduction: Individual centres in the UK often report good survival rates for patients with neuroendocrine tumours (NETs), however national survival data has not been available.
Conference: 15th Annual ENETS conference (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: Tracey Genus
#801 Normal Gastrointestinal Neuroendocrine Cells Lack E-cadherin
Introduction: E-cadherin plays a crucial role in the adhesion between epithelial cells and thus epithelial integrity. Moreover, germ line mutations in the E-cadherin gene (CDH1) causing loss of E-cadherin function (adhesion) leads to hereditary gastric cancer of the diffuse type, according to Laurén. Even sporadic gastric carcinomas of the diffuse type often lose E-cadherin expression due to mutations. Lack of E-cadherin has been recorded at an early phase in such carcinomas.
Conference: 11th Annual ENETS Conference (2014)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: Øyvind Hauso
Close
Notice

Dear conference participant,

Thank you for participating in the ENETS Virtual Conference 2020!

You now have the opportunity to view the webcasts, abstracts and e-posters via My ENETS. Don't miss on any of the exciting talks and take your time to view the clinical and basic science abstract sessions.

If you require a certificate of attendance, please log into My ENETS and select “Annual Conferences” from the side menu, then click on “My registrations” and select your registration for 2020. Please choose "Certificate o.A." to receive your certificate of attendance.

A note on CME accreditation:

ENETS has been liaising with UEMS regarding CME accreditation for the virtual conference. At present, we do not have a definitive answer. We will keep you updated.

 

Wishing you all the best,

The entire ENETS team